Home Tags AACR

Tag: AACR

AACR 2016: Companion and Complementary Diagnostics

Over the last decade, Targeted Therapies, Personalized and Precision Medicine have become part of our vocabulary, representing a new way of thinking in how...

American Association for Cancer Research (AACR) – What to Expect at...

This year, the American Association for Cancer Research (AACR) will host their annual meeting from April 16 to 20, 2016 in the Ernest N....

Mersana and Recepta Sign Agreement for Novel Antibody

Cambridge based Mersana Therapeutics and Recepta Biopharma, a clinical stage Brazilian biotechnology company, have entered into an exclusive license agreement in which Mersana will...

Improving Tumor Targeting Through Nanoparticle Encapsulation of Miniaturized Biologic Drug Conjugates

During the annual meeting of the American Association for Cancer Research (AACR) in Philadelphia, Penn, earlier this year, Massachusetts based Blend Therapeutics, Inc., a company...

Novel Anti-CD22 Antibody-Drug Conjugate Shows Positive Pre-clinical Activity

The 106th Annual Meeting of the American Association for Cancer Research (AACR) being held April 18-22, 2015 in Philadelphia, PA, included a poster presentation...
Photo: Before the pandemic - the annual meeting of the AACR/American Association for Cancer Research: Photo courtesy: 2015 AACR/Todd Buchanan.

XMT-1522 Demonstrates Potent Activity in Low HER2-Expressing Tumor Models

Preclinical data for XMT-1522, a novel HER2-targeting therapy based on Mersana Therapeutics' Dolaflexin platform, the company's most advanced Fleximer® proprietary immunoconjugate technology, demonstrates significant anti-cancer activity...
AACR Annual Meeting 2014

Refined Dosing Strategy for IMGN853 Achieves Objective

Data presented at the annual meeting of the American Association for Cancer Research (AACR) being held in San Diego, CA. shows clinical activity with IMGN853 (ImmunoGen), an antibody drug conjugate or ADC currently in Phase I clinical testing for the treatment of folate receptor α (FRα)-positive cancers, including ovarian, endometrial, lung and other cancers, starting at doses of 3.3 mg/kg.
Leukemia

Ongoing Phase I Clinical Trial of SGN-CD19A Demonstrates Encouraging Activity and...

Phase I interim data from a clinical trial with SGN-CD19A being developed for the treatment of B-cell malignancies, including acute lymphoblastic leukemia or ALL -- shows...

Phase I Trial of SGN-LIV1A Initiated in LIV-1-Positive Metastatic Breast Cancer

A new phase I clinical trial was initiated late October 2013 to evaluate SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer. SGN-LIV1A is based...

Phase I Trial of Seattle Genetics’ SGN-LIV1A for Patients with LIV-1-Positive...

A new phase 1 clinical trial evaluating SGN-LIV1A for patients with LIV-1-positive metastatic breast cancer has started. SGN-LIV1A utilizes Seattle Genetics’ industry-leading antibody-drug conjugate...